Poster Presentation to Spotlight Ongoing Phase 1 Clinical Trial of EVOLVE104
Oral and Poster Presentations to Highlight Preclinical Data Demonstrating Ability of EVOLVE Platform to Drive Enhanced T Cell Activity through Integrated CD2 Costimulation
BRANFORD, Conn., April 14, 2026 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, a clinical-stage immuno-oncology company developing a new class of multi-specific T cell engagers with integrated CD2 costimulation, today announced that new data highlighting its novel EVOLVE T cell engager platform will be presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The conference is being held April 17-22, 2026, in San Diego, California.
Details of the company's presentations at the AACR conference are as follows:
Oral Minisymposium Presentation #4055:
- Title: Integrated CD2-costimulation on CD3 T cell engager EVOLVE platform yields differentiated and superior T cell effector profile
- Presenting Author: Emma Stewart, Ph.D., EvolveImmune Therapeutics
- Session Title: Advances in Therapeutic Antibodies
- Session Date/Time: Monday, April 20, 2026, 2:30 – 4:30 p.m. PT
- Location: Ballroom 20 CD – Upper Level – Convention Center
Poster Presentation #CT079:
- Title: EIU-104101: A first-in-human phase 1a/1b study of EVOLVE104, a trispecific CD3×CD2×ULBP2/5/6 T cell engager, in advanced urothelial and squamous cell carcinomas
- Presenting Author: Tony Fiorino, M.D., Ph.D., EvolveImmune Therapeutics
- Session Title: Phase I Clinical Trials in Progress
- Session Date/Time: Monday, April 20, 2026, 9:00 a.m. – 12:00 p.m. PT
- Location: Poster Section 51; Poster Board #10
Poster Presentation #5594:
- Title: Pharmacological integration of CD3 and CD2 signaling triggers formation of a CD2 corolla that boosts T cell activation
- Presenting Author: Sergio Trombetta, Ph.D., EvolveImmune Therapeutics
- Session Title: T Cell Engagers 2/Antibody-Drug Conjugates 1
- Session Date/Time: Tuesday, April 21, 2026, 2:00 – 5:00 p.m. PT
- Location: Poster Section 8; Poster Board #13
About EVOLVE104
EVOLVE104 is a next-generation trispecific T cell engager that binds CD3 and CD2 on T cells and the tumor-associated antigens ULBP2/5/6, which have limited expression in normal human tissues and are found on a number of epithelial-derived malignancies, including urothelial carcinoma and a broad array of squamous cell carcinomas. In preclinical studies, EVOLVE104 has demonstrated compelling single-agent activity and combination activity with anti-PD-1 therapy, the ability to reinvigorate dysfunctional T cells, and a promising safety profile. EVOLVE104 is currently being studied in a first-in-human phase 1 clinical trial in subjects with advanced, relapsed or refractory solid tumors (NCT07217171).
About EvolveImmune Therapeutics
EvolveImmune Therapeutics, Inc. is an immuno-oncology company developing first-in-class, multi-specific T cell engagers derived from its EVOLVE platform, which have been inspired by a generation of discoveries in T cell immunology. EVOLVE molecules leverage the power of integrated CD2 costimulation to overcome the therapeutic challenges of cancer cell resistance to current immunotherapies in a range of solid tumors and hematological cancers. The EVOLVE platform has generated a pipeline of internal and partnered programs, the most advanced of which, EVOLVE104, is in active clinical development. For more information, please visit: www.evolveimmune.com.
CONTACT: Contacts: EvolveImmune Therapeutics Stephen Bloch, M.D. Chief Executive Officer 860-856-7104 info@evolveimmune.com Stellar Red PR (on behalf of EvolveImmune Therapeutics) Tim Brons (Media) 646-319-8981 tbrons@stellarredPR.com
